Hoth Therapeutics, Inc. (HOTH) Wednesday reported positive results from the preclinical study of its lead drug candidate HT-ALZ for the treatment of Alzheimer's disease.
HT-ALZ has shown significant cognitive and behavioral benefits in APP/PS1 mouse models of Alzheimer's disease. The study demonstrated that chronic oral administration of HT-ALZ led to marked improvement in memory, reduction of anxiety-like behavior, and enhanced sensorimotor gating, all without impairing motor function. Additionally, treatment with HT-ALZ led to a rapid 15 percent reduction in brain interstitial fluid Aß levels.
The company plans to advance HT-ALZ into clinical development.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.